The glucagon-like peptide-1 receptor agonists and newer triple agonists like retatrutide have a well-documented safety profile, but they are not without risks
GLP-1 are transforming lives, yet lasting success depends on more than just the prescription
[4] This is not a formal contraindication under UK/EU labelling, but individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) are typically excluded from trials pending further data
According to the SURMOUNT-1 clinical trial, patients using tirzepatide at the highest dose (15 mg weekly) experienced up to 22.5% total body weight loss over 72 weeksgreater than what is typically seen with semaglutide GLP-1
Only use laboratory-grade solvents like bacteriostatic or sterile water
Tirzepatide, a dual GLP-1 and GIP receptor agonist, works by regulating appetite and blood sugar through two distinct hormonal pathways